ABSTRACT
OBJECTIVES: Pulmonary metastasectomy for sarcoma is a widely accepted practice. Nevertheless, no previous studies has been reported the outcomes following metastasectomy compared with chemotherapy for patients with resectable and isolated pulmonary metastases. Our aim is to compare these modalities for the subset of patients with resectable metastases. Furthermore, the outcomes for patients with unresectable lung metastases are reported. METHODS: Sarcoma patients with isolated lung metastases were identified and their computed axial tomography scans were reviewed by a thoracic surgeons' committee. Patients were divided into three groups: A: patients with resectable metastases treated with metastasectomy (n=29), B: patients with resectable metastases who received systemic therapy (n=17) and C: patients with unresectable metastases (n=25). Survival outcomes were plotted and compared through log-rank test for osteosarcoma and non-osteosarcoma patients. RESULTS: Seventy-one patients (32 with osteosarcoma and 39 with non-osteosarcoma) were eligible. Progression-free survival (PFS) was superior in patients who belonged to Group A compared with Groups B and C (8.0, 4.3 and 2.2 months, respectively, P=0.0002). Furthermore, overall survival (OS) was superior in patients who belonged to Group A compared with Groups B and C (39.6, 20.0 and 7.8 months, respectively, P<0.0001). A subanalysis for osteosarcoma patients showed superior PFS and OS for Group A vs B (median PFS 21.6 and 3.65 months, respectively, P=0.011 and median OS 34.0 and 12.4 months, respectively, P=0.0044). For non-osteosarcoma patients, there were no such significant survival differences between Groups A and B. Overall, patients who belonged to Group A had significantly lower mean percentage of their follow-up time spent admitted at hospital, and a trend towards lower requirements for home oxygen therapy. CONCLUSIONS: Pulmonary metastasectomy is associated with improved survival of osteosarcoma patients with resectable lung metastases. For non-osteosarcoma patients, the survival benefit of metastasectomy over chemotherapy is uncertain and warrants further evaluation. Patients with unresectable metastases have poor prognosis.
Subject(s)
Home Care Services , Hospitalization , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Metastasectomy/methods , Osteosarcoma/secondary , Oxygen Inhalation Therapy , Pneumonectomy/methods , Sarcoma/secondary , Sarcoma/surgery , Adult , Chi-Square Distribution , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Length of Stay , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/mortality , Male , Metastasectomy/adverse effects , Metastasectomy/mortality , Osteosarcoma/diagnostic imaging , Osteosarcoma/mortality , Osteosarcoma/surgery , Patient Discharge , Pneumonectomy/adverse effects , Pneumonectomy/mortality , Retrospective Studies , Risk Factors , Sarcoma/diagnostic imaging , Sarcoma/mortality , Time Factors , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Ectopic pancreas in the thoracic cavity is uncommon. We report 2 patients who had large cystic or cystic-solid masses containing pancreatic tissue in the thorax. Their clinical presentation, imaging, and pathologic findings are described. Both patients underwent total surgical resection of the masses, with no recurrence.
Subject(s)
Choristoma , Pancreas , Thoracic Diseases , Adult , Choristoma/diagnosis , Choristoma/surgery , Humans , Male , Middle Aged , Thoracic Diseases/diagnosis , Thoracic Diseases/surgeryABSTRACT
Thymic carcinoma arising within a thymolipoma has not been reported previously. The authors present a unique case of thymoma and undifferentiated thymic carcinoma arising within a thymolipoma in a 36-year-old woman. The bulk of the resected mass was composed of benign fatty tissue admixed with foci of unremarkable thymic tissue; however, it also harbored a central solid mass showing undifferentiated thymic carcinoma associated with a type B2 thymoma. The carcinoma cells were positive for cytokeratin AE1/AE3, cytokeratin 19, and cytokeratin 8/18. They were negative for vimentin, cytokeratin 7, cytokeratin 20, CD5, epithelial membrane antigen, CD30, placental alkaline phosphatase, carcinoembryonic antigen, CD99, leukocyte common antigen, Epstein-Barr virus, inhibin alpha, and protein gene product 9.5. Rare tumor cells showed positive staining for chromogranin and synaptophysin.
